AI-driven drug discovery Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
19:11
Jan 05
Stan DeLaney Leads disruptive change research at Morgan Stanley Investme… Morgan Stanley
AI can speed drug discovery.
The speaker is positive on AI-driven drug discovery, arguing AI can identify new compounds that are more efficacious or have lower side-effect profiles, and that speeding the drug discovery process should be beneficial.
AI-driven drug discovery
MED

About AI-driven drug discovery Investor Commentary

Across the available history and selected sources, Buzzberg tracks AI-driven drug discovery across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Stan DeLaney.